The topic is short and compact
The stratum corneum of infants is up to 30 % thinner than that of adults, which requires mild formulations that account for a higher absorption rate.
EU Cosmetics Regulation 1223/2009 requires a specific safety assessment with higher safety margins for children under three years of age.
Preservatives such as propylparaben are restricted in the nappy area to avoid irritation under occlusive conditions.
So läuft die Entwicklung bei Labtree
1
Konzeptionierung
2
Bemusterung – Standardmuster in 24 h
3
Individualisierung
4
Prototyping
5
Produktion
White Label 2–3 Monate · Private Label 3–6 Monate · Produktion ab 1.000 Stück
Developing cosmetics for infant skin and sensitive skin requires a precise understanding of epidermal physiology. The skin of newborns and infants is not simply a miniature version of mature adult skin; it is a developing organ undergoing rapid functional and structural maturation. Clinical histological evaluations show that the stratum corneum in infants is up to 30% thinner than in adults, while total epidermal thickness is reduced by up to 20%. In addition, infant corneocytes and keratinocytes are significantly smaller, reflecting accelerated cell turnover combined with an immature cellular cohesion framework.
This reduced structural depth directly compromises the mechanical permeability barrier. The infant stratum corneum also contains a lower concentration of natural moisturizing factor (NMF) than adult skin, so its water-holding capacity remains limited and continues to mature during the first year of life, with rapid sorption and desorption of water. As a result, transepidermal water loss can fluctuate sharply when the skin is exposed to dry atmospheric conditions or surfactants, leaving it vulnerable to subclinical irritation and microbial penetration.
Physiological parameter | Infant epidermis (< 3 years) | Mature adult epidermis | Implication for formulation |
|---|---|---|---|
Stratum corneum thickness | Up to 30% thinner than in adults | Fully stratified (approx. 10–20 µm) | Requires non-penetrating, biomimetic lipids |
Body surface area to weight ratio | Approx. 2.3 times higher ratio than in adults | Standard baseline ratio (approx. 0.026 m²/kg) | Multiplies relative systemic exposure |
Skin surface pH at birth | Neutral to slightly alkaline (pH 6.3–7.5) | Slightly acidic acid mantle (pH 4.5–5.5) | Requires physiological pH buffering (pH 5.0–5.5) |
Corneocyte size | Approx. 20% smaller than in adults (granular cells 10% smaller) | Baseline reference size, fully cross-linked corneocytes | Requires mild, non-drying surfactants |
A decisive pharmacokinetic factor for the safety of infant products is the ratio of body surface area to body weight. In newborns this ratio is approximately 2.3 times higher than in adults, and in premature infants and low-birth-weight infants it is higher still, so applying a product to a large body area delivers a considerably higher dose per unit of body weight. Transdermal absorption in newborns and young infants is further enhanced because the stratum corneum and epidermis are thinner and less mature, shortening the permeation pathway and increasing the risk of unintended systemic uptake. Combined with immature hepatic clearance enzymes during the first year of life, topical substances that cross the permeable stratum corneum enter systemic circulation at proportionally higher doses. Technical product development must therefore account for these physiological weak points through strict raw material exclusions and precise exposure calculations.
Physiology of infant and sensitive skin: key characteristics
Developing cosmetics for infant skin and sensitive skin requires a precise understanding of epidermal physiology. The skin of newborns and infants is not simply a miniature version of mature adult skin; it is a developing organ undergoing rapid functional and structural maturation. Clinical histological evaluations show that the stratum corneum in infants is up to 30% thinner than in adults, while total epidermal thickness is reduced by up to 20%. In addition, infant corneocytes and keratinocytes are significantly smaller, reflecting accelerated cell turnover combined with an immature cellular cohesion framework.
This reduced structural depth directly compromises the mechanical permeability barrier. The infant stratum corneum also contains a lower concentration of natural moisturizing factor (NMF) than adult skin, so its water-holding capacity remains limited and continues to mature during the first year of life, with rapid sorption and desorption of water. As a result, transepidermal water loss can fluctuate sharply when the skin is exposed to dry atmospheric conditions or surfactants, leaving it vulnerable to subclinical irritation and microbial penetration.
Physiological parameter | Infant epidermis (< 3 years) | Mature adult epidermis | Implication for formulation |
|---|---|---|---|
Stratum corneum thickness | Up to 30% thinner than in adults | Fully stratified (approx. 10–20 µm) | Requires non-penetrating, biomimetic lipids |
Body surface area to weight ratio | Approx. 2.3 times higher ratio than in adults | Standard baseline ratio (approx. 0.026 m²/kg) | Multiplies relative systemic exposure |
Skin surface pH at birth | Neutral to slightly alkaline (pH 6.3–7.5) | Slightly acidic acid mantle (pH 4.5–5.5) | Requires physiological pH buffering (pH 5.0–5.5) |
Corneocyte size | Approx. 20% smaller than in adults (granular cells 10% smaller) | Baseline reference size, fully cross-linked corneocytes | Requires mild, non-drying surfactants |
A decisive pharmacokinetic factor for the safety of infant products is the ratio of body surface area to body weight. In newborns this ratio is approximately 2.3 times higher than in adults, and in premature infants and low-birth-weight infants it is higher still, so applying a product to a large body area delivers a considerably higher dose per unit of body weight. Transdermal absorption in newborns and young infants is further enhanced because the stratum corneum and epidermis are thinner and less mature, shortening the permeation pathway and increasing the risk of unintended systemic uptake. Combined with immature hepatic clearance enzymes during the first year of life, topical substances that cross the permeable stratum corneum enter systemic circulation at proportionally higher doses. Technical product development must therefore account for these physiological weak points through strict raw material exclusions and precise exposure calculations.
EU regulatory requirements and safety assessment
Under the EU Cosmetics Regulation 1223/2009 (Regulation (EC) No 1223/2009), cosmetic products placed on the European market must undergo a rigorous safety assessment documented in the Cosmetic Product Safety Report (CPSR). For products specifically intended for children under three years of age, the Regulation requires a separate safety assessment in Part B of the safety report. Safety assessors cannot rely on general toxicological profiles for adults; they must apply increased safety margins and exposure assessments specifically tailored to infant physiology.
Official guidelines from the European Commission's Scientific Committee on Consumer Safety (SCCS), available at ec.europa.eu, define how exposure to cosmetic products is assessed for different age groups, including children, and provide age-stratified default values for body weight and product application amounts. The Margin of Safety (MoS) for raw materials in baby care is evaluated against these conservative defaults, which are tailored to highly exposed nappy and body areas. The safety assessor must explicitly review the toxicological profile, systemic availability, chemical purity and potential aggregate exposure of each individual component.
Review of toxicological endpoints, including the No Observed Adverse Effect Level (NOAEL) and systemic exposure doses (SED), adjusted for infant body surface area.
Detailed justification for every preservative, chelating agent and emulsifier in the context of impaired barrier function and occlusive nappy areas.
Exclusion of CMR substances (carcinogenic, mutagenic or toxic to reproduction) and strict limits for trace impurities such as heavy metals, 1,4-dioxane and free ethylene oxide.
Review of primary packaging materials to ensure no chemical migration into the bulk formulation occurs during storage.
To achieve compliance with the EU Cosmetics Regulation, this documentation must be compiled in the Product Information File well before pilot production begins. Every raw material certificate of analysis (CoA), every safety data sheet (SDS) and every microbiological specification must be checked against the SCCS opinions to avoid regulatory rejection or forced reformulations late in the development cycle.
Raw material selection and excluded ingredients
Developing formulations for vulnerable groups requires a strict ingredient exclusion policy. Conventional cosmetic ingredients that deliver pleasant fragrance, vivid colour or long shelf life in make-up and skincare development for adults often carry serious sensitisation risks in products for babies and sensitive skin. Raw material selection must therefore focus on high-purity, low-reactivity substances with an extensive clinical safety history.
Fragrances are the most common cause of contact dermatitis in sensitive skin. Essential oils and complex perfumes containing recognised fragrance allergens (such as limonene, linalool, citral and farnesol) must be avoided entirely. Natural plant extracts also carry hidden risks for the formulation: unrefined botanical materials frequently contain complex mixtures of terpenes, polyphenolic oxidants and natural impurities that can trigger immediate Type I or delayed Type IV allergic reactions on compromised skin.
Ingredient category | Regulatory / technical status | Main reason for exclusion | Compliant formulation alternative |
|---|---|---|---|
Synthetic and natural fragrances | Excluded in leave-on care for babies & sensitive skin | Primary trigger of allergic contact dermatitis | Unfragranced, odour-neutral raw material bases |
Essential oils & botanical terpenes | Strictly limited / excluded | Phototoxicity, oxidation by-products, sensitisation | High-purity isolated actives (e.g. bisabolol, allantoin) |
Propylparaben & butylparaben | Prohibited in leave-on care for the nappy area | Increased penetration under occlusive nappy conditions | Multifunctional glycols & organic acid systems |
Harsh anionic surfactants (SLS) | Excluded in rinse-off formulas for babies | Protein denaturation and stripping of stratum corneum lipids | Amphoteric & non-ionic surfactants (e.g. glucosides) |
Azo dyes & synthetic colourants | Excluded in all baby formulations | Potential skin irritation without functional benefit | Plain uncoloured emulsions and zinc oxide suspensions |
Regulatory limits also impose targeted prohibitions on certain preservatives. Under Regulation (EU) No 1004/2014, the European Commission has banned the use of propylparaben and butylparaben in cosmetic leave-on products intended for application in the nappy area of children under three years of age. This restriction reflects the occlusive conditions created by nappies, where heat, urine and faecal enzymes damage the epidermal barrier, multiplying topical penetration and aggravating irritation.
Formulation strategies for sensitive skin care
Developing robust formulations for sensitive skin requires a balance between actively repairing the skin barrier and inert, non-irritating carrier systems. The primary objective is to support the skin's lipid matrix without disturbing the acid mantle. Emulsions should be formulated within a physiological pH range of 5.0 to 5.5, using physiological buffering agents such as lactic acid and sodium citrate to maintain the dermal enzymatic balance and inhibit pathogenic colonisation.
Emulsifier selection is critical. Conventional ethoxylated surfactants (PEGs) and ionic emulsifiers with a high HLB value can dissolve and strip the stratum corneum's own lipids during washing or sweating, leading to barrier breakdown. Products for sensitive skin instead use biomimetic lamellar emulsifiers based on hydrogenated phosphatidylcholine, polyglyceryl esters and alkyl glucosides. These emulsifiers mimic the natural multilamellar lipid layers of healthy human skin and preserve moisture without irritation.
Selecting high-purity inert lipid phases: using pharmaceutical-grade caprylic/capric triglycerides, squalane and jojoba or sunflower oils stripped of unrefined components, with controlled peroxide values.
Incorporating skin-identical barrier lipids: integrating physiological ratios of ceramides (NP, AP, EOP), phytosphingosine and cholesterol to rebuild the lipid lamellae.
Hydrocolloid stabilisation: using pharmaceutical-grade xanthan, sclerotium gum or cross-linked biopolymers to stabilise viscosity without requiring high surfactant loads.
Refining the sensory profile: optimising spreadability on the skin and absorption through precise adjustments of phase ratios, ensuring the formulation forms a non-tacky protective film.
Achieving this balance requires rigorous laboratory work. Translating a concept into a stable emulsion calls for iterative testing in dedicated development facilities. Experienced teams run early laboratory sampling to test sensory profiles, viscosity shifts and the droplet size distribution of the emulsion under high-shear homogenisation before moving on to production feasibility.
The preservation dilemma and mandatory testing
Preserving baby and sensitive-skin cosmetics poses a profound technical dilemma: the formulation must deliver sufficient antimicrobial activity to prevent dangerous microbial growth while remaining gentle enough to cause no irritation whatsoever on delicate skin. Conventional broad-spectrum biocides such as isothiazolinones, formaldehyde releasers and halogenated compounds are unacceptable because of their sensitisation potential. Instead, formulators use hurdle technology, combining multifunctional boosters (such as ethylhexylglycerin, caprylyl glycol and glyceryl caprylate) with mild organic acids (such as sodium benzoate, potassium sorbate or levulinic acid) at controlled pH values.
Because these mild preservation systems operate within narrower windows of efficacy, antimicrobial protection must be verified in accordance with ISO 11930. In this standardised preservative challenge test, the formulation is inoculated with five defined reference organisms: Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Aspergillus brasiliensis (formerly A. niger). Colony counts are measured after 7, 14 and 28 days to determine whether the formulation meets the required log-reduction criteria.
Organism group | Test strains (ISO 11930) | Requirement, Criterion A (day 7 / 14 / 28) | Requirement, Criterion B (day 14 / 28) |
|---|---|---|---|
Bacteria | S. aureus, E. coli, P. aeruginosa | ≥ 3 log reduction at day 7, ≥ 3 log and no increase at day 14, no increase at day 28 | ≥ 3 log reduction at day 14 and no increase at day 28 |
Yeast | Candida albicans | ≥ 1 log reduction at day 7, ≥ 1 log and no increase at day 14, no increase at day 28 | ≥ 1 log reduction at day 14 and no increase at day 28 |
Mould / fungus | Aspergillus brasiliensis | No increase at day 14; ≥ 1 log reduction at day 28 | No increase on the initial count at day 14 and no increase versus the day 14 count at day 28 |
Beyond microbiological validation, comprehensive stability testing is essential. Formulations must undergo twelve weeks of accelerated thermal stability testing at elevated temperature and controlled humidity, real-time testing under ambient conditions, and repeated freeze-thaw cycles between sub-zero and warm storage conditions. These stress conditions verify that emulsions remain resistant to phase separation, creaming, syneresis and the degradation of active ingredients across the entire retail life cycle.
Packaging compatibility and packaging migration
A stable formulation in a beaker can fail completely once filled into the commercial primary packaging. The interaction between packaging materials and sensitive cosmetic bulks is a frequent cause of late-stage launch failures. Plastic packaging, in particular polyolefins such as polyethylene (PE) and polypropylene (PP), can interact chemically and physically with cosmetic formulations through sorption, permeation and leaching.
A key risk is the sorption of lipophilic preservatives and booster glycols into the container walls. Certain antimicrobial compounds migrate out of the continuous aqueous phase and bind irreversibly to non-polar plastic polymers. This depletion lowers the active preservative concentration in the bulk product below minimum inhibitory concentrations, meaning a formulation that passed early laboratory tests can fail on preservation during its shelf life. In addition, volatile formulation components can permeate outward through thin container walls, while atmospheric oxygen penetrates inward and degrades oxidation-sensitive lipids.
Sorption of preservatives: adsorption and absorption of organic acids or glycols into plastic matrices, which makes analytical verification before and after the 12-week storage period necessary.
Extractables and leachables: release of plastic additives, lubricants, plasticisers or residual monomers from lower-grade polymers into the cosmetic bulk.
Gas permeation: oxygen and water vapour transmission through single-layer packaging, leading to localised microbial growth or drying out of the emulsion.
Stress cracking: environmental stress cracking of closure caps and pump housings, caused by surfactant exposure under mechanical stress.
To mitigate these sources of error, technical assessments must verify packaging compatibility using the final formulation in its definitive production packaging. Airless systems with internal EVOH barrier layers (ethylene vinyl alcohol) or opaque containers made of virgin PP offer optimal protection against oxygen ingress, container sorption and recontamination by the consumer during daily use.
The transition from a small laboratory beaker batch to an industrial production vessel holding several hundred kilograms is one of the most critical phases in cosmetic product development. Formulations for sensitive skin respond extremely sensitively to processing kinetics: mixing shear rates, heating and cooling gradients, impeller configurations and the order of raw material addition directly determine the final droplet size of the emulsion, its viscosity and its rheological stability.
Scale-up from the laboratory to production requires validating homogenisation protocols in industrial vacuum processing systems. High-shear rotor-stator homogenisers must be calibrated to avoid over-shearing sensitive polymer networks or introducing micro air bubbles, which impair preservative efficacy and the physical appearance. Temperature control during the incorporation of actives is equally critical: heat-sensitive lipids and organic acid preservatives must be added below defined temperature thresholds (typically < 40 °C) to prevent thermal degradation.
Raw material quarantine and incoming goods inspection: verification of raw material purity, bioburden and compliance with heavy metal limits against strict specifications for infant products.
Cleanroom hygiene protocols: disinfection of mixing vessels, transfer lines and filling heads using validated CIP (clean-in-place) procedures to eliminate bioburden.
In-process controls (IPC): real-time monitoring of batch temperature, pH value, viscosity and the microscopic emulsion droplet distribution during manufacture.
Comprehensive batch release testing: microbiological count determination of the finished batch (total viable count < 100 CFU/g, absence of specified pathogens) before commercial release.
Industrial manufacturing must strictly follow Good Manufacturing Practice (GMP) in accordance with ISO 22716. ISO 22716 defines mandatory controls for personnel hygiene, plant cleaning, equipment maintenance and complete batch documentation and traceability from the raw material lot to the finished packaged unit. Labtree operates as a specialised B2B cosmetic developer and manufacturer, combining laboratory formulation engineering with ISO 22716-compliant production to deliver safe, stable and commercially viable skincare products for babies and sensitive skin.
Sources: pmc.ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov · pubmed.ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov · health.ec.europa.eu · ec.europa.eu · microbe-investigations.com · microchemlab.com · registrarcorp.com
More useful links
FAQ
What distinguishes infant skin from adult skin in product development?
Infant skin is not a miniature version of adult skin: the stratum corneum is up to 30 % thinner, the corneocytes are smaller and the body surface area to weight ratio is higher. This results in faster percutaneous absorption, which is why formulations must avoid harsh surfactants and potential allergens.
Which EU requirements apply to baby cosmetics?
For products intended for children under three years of age, the EU Cosmetics Regulation 1223/2009 requires a separate Cosmetic Product Safety Report. The safety assessor must apply increased Margins of Safety (MoS) and explicitly justify the use of every single ingredient.
Why are certain preservatives restricted in baby products?
Because of the thinner skin barrier and the occlusive conditions in the nappy area, the absorption of ingredients is significantly increased. The EU explicitly restricts preservatives such as butylparaben and propylparaben in products intended for the nappy area of children under three years of age.
What is the ISO 11930 preservative challenge test?
ISO 11930 is the mandatory standardised test for evaluating the antimicrobial protection of a cosmetic product. It verifies that the preservation system effectively protects water-containing formulations against microbial contamination over the entire intended shelf life.
How does packaging affect preservative efficacy in sensitive-skin cosmetics?
Plastic packaging can bind preservatives out of the formulation, i.e. sorb them. This packaging migration can reduce the active preservative concentration below the validated thresholds. Stability testing and ISO 11930 testing must therefore always be carried out in the final primary packaging.
Why is ISO 22716 important for sensitive-skin cosmetics?
ISO 22716 defines Good Manufacturing Practice (GMP) for cosmetic production. It prescribes rigorous equipment qualification, complete batch traceability and microbiological release testing, so that baby and sensitive-skin cosmetics are manufactured safely and consistently.
